PRME — Prime Medicine Cashflow Statement
0.000.00%
Last trade - 00:00- $740.09m
- $526.81m
- $2.98m
Annual cashflow statement for Prime Medicine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.41 | -165 | -122 | -198 | -196 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -4.21 | 100 | 24.1 | 25.7 | 35.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.164 | 31.2 | -35.4 | 2.65 | 31.1 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -5.54 | -34.1 | -132 | -165 | -123 |
| Capital Expenditures | -0.639 | -4.15 | -16.1 | -8.72 | -7.29 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.423 | -69.5 | -31 | 27.4 | 75.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.06 | -73.6 | -47.1 | 18.7 | 68.5 |
| Financing Cash Flow Items | -0.02 | -1.09 | -4.04 | 0 | 6 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 34.9 | 269 | 181 | 0.655 | 196 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 28.3 | 162 | 2.57 | -146 | 141 |